In this regard, cellular panning approaches were already successfully used to identify novel antibodies targeting so far unknown tumor-associated antigens like the C-type lectin-like molecule-1 on acute myeloid leukemia (AML) cells or tumor-specific peptides of oncogenes (RAS and TP53) presented on human leukocyte antigens (HLA) (8–10). The gene discussed is CLEC12A; the disease is acute myeloid leukemia.